Christelle Chantalat‐Auger

Better 10‐Year Cerebrovascular Outcome After Transplant Than on Standard‐Care in Sickle Cell Anemia: DREPAGREFFE Trial

Francoise Bernaudin, Suzanne Verlhac, Elisabeth Ducros-Miralles, Cécile Arnaud et autres

Management of cerebral vasculopathy in sickle cell anemia (SCA) includes standard-care, that is, chronic transfusion (CT) or hydroxyurea, and hematopoietic cell transplantation (HCT). DREPAGREFFE-1 (December 2010/June 2013), a French multicenter trial, was the first prospective trial comparing standard-care to match sibling donor …

fr, ch, gp, in, us (code pays fourni par la source)

Autoimmune Features in Sickle Cell Patients: A New Explanation for Liver Damage?

Aude Mausoléo, Pascale Chrétien, A. Laurent-Bellue, L. Rocher et autres

fr (code pays fourni par la source)

Cardiopulmonary Hemodynamic Determinants of Long-Term Survival in Sickle Cell Disease: Insights from the ETENDARD Study

Laurent Savale, Thomas d’Humières, Athénaïs Boucly, Anoosha Habibi et autres

Abstract Rationale Pulmonary hypertension is a serious cardiopulmonary complication of sickle cell disease, but the prognostic impact of hemodynamic parameters remains poorly defined. Objectives This study aimed to assess the clinical and long-term prognostic relevance of hemodynamic parameters in sickle cell disease. …

fr, mq (code pays fourni par la source)

Outcome of Cerebral Vasculopathy and Cognitive Performances 10 Years Post-Enrollment in the Drepagreffe Trial Comparing Allogeneic Stem Cell Transplantation to Standard-Care in Children with Sickle Cell Anemia and History of Abnormal Cerebral Velocities

Françoise Bernaudin, Suzanne Verlhac, Elisabeth Ducros-Miralles, Cécile Arnaud et autres

Abstract DREPAGREFFE-1 (NCT01340404), was the first prospective trial comparing allogeneic stem cell transplantation (alloSCT) to standard-of-care (SoC) in children with sickle cell anemia (SCA). This French multicenter trial was defined by the random-availability of a matched-sibling donor (MSD). Inclusion criteria were SS/Sb0 …

fr, gp (code pays fourni par la source)

Unique Nature of Sickle Cell Diastolic Cardiomyopathy: A Tailored Echocardiographic Definition to Refine Prognostic Stratification in Young Adults

Thomas D'Humieres, Théo Simon, Kristoffer Grundtvig Skaarup, Laurent Savale et autres

Background: Cardiovascular complications are the leading cause of mortality in sickle cell anemia (SCA) patients. While cardiac diastolic dysfunction (DD) is a well-documented mechanism contributing to heightened morbidity and mortality, the unique hemodynamic conditions inherent to SCA pose challenges to the application …

fr, dk, mq, us (code pays fourni par la source)

Pulmonary hypertension in sickle cell disease

Salma Al Kahf, Anne Roche, Audrey Baron, Christelle Chantalat‐Auger et autres

Sickle cell disease (SCD) is a complex genetic disorder that has long challenged both patients and healthcare professionals. One of its chronic and debilitating complications is pulmonary hypertension (PH). SCD-associated PH is often post-capillary, secondary to left heart disease. It can also …

fr (code pays fourni par la source)

Autoimmunity in sickle cell disease: Analysis of a large cohort of adult patients

Aude Mausoléo, Lisa Fredeau, Pascale Chrétien, Salima Hacein‐Bey‐Abina et autres

Sickle cell disease (SCD) is a genetic hemoglobinopathy leading to chronic hemolysis punctuated by vaso-occlusive episodes and responsible for chronic organ damages.1 While the association between SCD and some autoimmune diseases (AIDs) has been reported, the diagnosis of AIDs in this context …

fr (code pays fourni par la source)

Anti-C5 antibody treatment for delayed hemolytic transfusion reactions in sickle cell disease

Aline Floch, Alexandre Morel, Fabian Zanchetta-Balint, Catherine Cordonnier-Jourdin et autres

CASE REPORTS Anti-C5 antibody treatment for delayed hemolytic transfusion reactions in sickle cell diseaseContinuous variables are expressed as means ± one standard deviation (SD) or medians (MD, [interquartile range]), depending on whether they are normally or asymmetrically distributed.Categorical variables are expressed as …

fr (code pays fourni par la source)

Prognosis of patients with sickle cell disease and COVID-19: a French experience

Jean‐Benoît Arlet, Gonzalo De Luna, D. Khimoud, Marie‐Hélène Odièvre et autres

fr (code pays fourni par la source)

Treatment of Delayed Hemolytic Transfusion Reactions in Sickle Cell Disease Patients By an Anti-C5 Antibody

Aline Floch, Alexandre Morel, Fabian Zanchetta-Balint, Catherine Cordonnier-Jourdin et autres

Background: Delayed hemolytic transfusion reaction (DHTR) is an unpredictable and severe complication of transfusion, especially in Sickle Cell Disease (SCD) patients (Habibi Am J Hematol 2016). The clinical presentation is a vaso occlusive crisis (VOC), often associated with one or more organ …

fr (code pays fourni par la source)

Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease

Laurent Savale, Anoosha Habibi, François Lionnet, Bernard Maître et autres

Rationale Precapillary pulmonary hypertension (PH) is a devastating complication of sickle cell disease (SCD). Little is known about the influence of the SCD genotype on PH characteristics. Objectives To describe clinical phenotypes and outcomes of precapillary PH due to SCD according to …

fr (code pays fourni par la source)

Traitement de l’hémolyse post-transfusionnelle retardée par un anti-C5 (Eculizumab) chez les patients drépanocytaires

Aline Floch, Alexandre Morel, Fabian Zanchetta-Balint, Catherine Cordonnier-Jourdin et autres

fr (code pays fourni par la source)